Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: E_K_S who wrote (33334)	1/23/2009 6:54:47 PM
From: Oblomov	Read Replies (1) \| Respond to of 78673

Although you directed your question to Paul, my own strategy is to buy shares in the second and third tier (in terms of market cap, not quality) of biotech/junior pharma, such as CEPH, SEPR, ILMN, VRTX, MDCO, AMRI. I believe that the 250MM - 8B market cap range is the sweet spot for major pharma on the hunt for acquisitions to restore their pipelines. Also, consider that the primary care marketing model that worked in the 90s and early 00s is dead. The growth doesn't exist there, and the PC therapies will come under pricing assault under Obama. There are some great opportunities with companies whose therapies are concentrated in critical care or oncology. These will be the key acquisition targets.